@inproceedings{inproceedings, title  = {{AMLITELIMAB REDUCES SERUM IL-13 IN A PHASE 2A CLINICAL TRIAL IN ATOPIC DERMATITIS WITHOUT IMPACTING T-CELL EXPANSION IN A T-CELL RECALL ASSAY}},

 url = {{}},

 year = {{2022}},

 month = {{1}},

 author = {{Weidinger S and Cork MJ and Reich A and Bieber T and Lucchesi D and Rynkiewicz N and Sainson RCA and Chen R and Prandi F and van Krinks C and Stebegg M et al}},

 volume = {{102}},

 journal = {{ACTA DERMATO-VENEREOLOGICA}},

 pages = {{19-20}},

 note = {{Accessed on 2025/10/26}}}